New Stock Debut | DUALITYBIO-B Listed on First Day with a 91.33% Opening Surge, Company is an ADC Innovative Drug Developer
I'm PortAI, I can summarize articles.
DUALITYBIO-B debuted on its first day of listing, opening with a rise of 105%, priced at HKD 195. The share price was set at HKD 94.6, with 17.3323 million shares issued, netting approximately HKD 1.513 billion. The company focuses on the research and development of antibody-drug conjugates (ADC), has two core products, and is conducting multiple clinical trials globally, establishing partnerships with several biopharmaceutical companies, with a total transaction value exceeding USD 6 billion
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments